EnginZyme is cell-free synthetic biology company focuses on enzyme immobilization.
EnginZyme’s cell-free synthetic biology platform marries the efficiency of the chemical industry with the power and diversity of biology.
EnginZyme was founded in 2014 by Robin Chatterjee, Samuel Härgestam and Karim Engelmark Cassimjee. The company is headquartered in Stockholm, Sweden, with offices in UK and US.
EnginZyme’s mission is to make biocatalysis the first choice for chemical process designers worldwide.
EnginZyme's cell-free synbio platform uses the power of biology, while at the same time reaching the efficiencies of the chemical industry. It seeks to solve one of the fundamental problems of our time: How to produce sustainable alternatives to plastics, nylons, rubbers, and the tons of other synthetics that are used on a daily basis, without compromising on cost-effectiveness.
EnginZyme’s technology platform combines the breadth and power of nature (enzymatic cascades) with the efficiency of the chemical industry (packed bed reactors) in a best-of-both-worlds technical solution.
EnginZyme has raised €6.4M in a Series A round on April 22, 2020. The investment was led by Sofinnova Partners. This new round brings EnginZyme's total funding to over €10M to date.